Biogen wins Euro MS approval, but loses patents.
Brower
V
V
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001709:Biotechnology / Q000191:economics; D004345:Drug Industry / Q000191:economics; D005062:European Union; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D007557:Israel; D009103:Multiple Sclerosis / Q000628:therapy*; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D010455:Peptides / Q000191:economics / Q000627:therapeutic use*; D011108:Polymers; D011994:Recombinant Proteins / Q000627:therapeutic use; D014481:United States
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D010455:Peptides; D011108:Polymers; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a